These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

145 related articles for article (PubMed ID: 8916978)

  • 1. The need for add-back with gonadotrophin-releasing hormone agonist therapy.
    Studd J; Leather AT
    Br J Obstet Gynaecol; 1996 Oct; 103 Suppl 14():1-4. PubMed ID: 8916978
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Add-back therapy in the treatment of endometriosis: the European experience.
    Edmonds DK
    Br J Obstet Gynaecol; 1996 Oct; 103 Suppl 14():10-3. PubMed ID: 8916980
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Should add-back therapy for endometriosis be deferred for optimal results?
    Kiesel L; Schweppe KW; Sillem M; Siebzehnrübl E
    Br J Obstet Gynaecol; 1996 Oct; 103 Suppl 14():15-7. PubMed ID: 8916982
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Add-back therapy for long-term use in dysfunctional uterine bleeding and uterine fibroids.
    Thomas EJ
    Br J Obstet Gynaecol; 1996 Oct; 103 Suppl 14():18-21. PubMed ID: 8916983
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Immediate and delayed add-back hormonal replacement therapy during ultra long GnRH agonist treatment of chronic cyclical pelvic pain.
    Al-Azemi M; Jones G; Sirkeci F; Walters S; Houdmont M; Ledger W
    BJOG; 2009 Nov; 116(12):1646-56. PubMed ID: 19735378
    [TBL] [Abstract][Full Text] [Related]  

  • 6. The prevention of bone loss in young women treated with GnRH analogues with "add-back" estrogen therapy.
    Leather AT; Studd JW; Watson NR; Holland EF
    Obstet Gynecol; 1993 Jan; 81(1):104-7. PubMed ID: 8416441
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Prevention of bone loss and hypoestrogenic symptoms by estrogen and interrupted progestogen add-back in long-term GnRH-agonist down-regulated patients with endometriosis and premenstrual syndrome.
    Mitwally MF; Gotlieb L; Casper RF
    Menopause; 2002; 9(4):236-41. PubMed ID: 12082359
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Comparison of the gonadotropin-releasing hormone agonist goserelin acetate alone versus goserelin combined with estrogen-progestogen add-back therapy in the treatment of endometriosis.
    Kiilholma P; Tuimala R; Kivinen S; Korhonen M; Hagman E
    Fertil Steril; 1995 Nov; 64(5):903-8. PubMed ID: 7589632
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Add-back therapy in the treatment of endometriosis: the North American experience.
    Moghissi KS
    Br J Obstet Gynaecol; 1996 Oct; 103 Suppl 14():14. PubMed ID: 8916981
    [No Abstract]   [Full Text] [Related]  

  • 10. Efficacy of tibolone as "add-back therapy" in conjunction with a gonadotropin-releasing hormone analogue in the treatment of uterine fibroids.
    Morris EP; Rymer J; Robinson J; Fogelman I
    Fertil Steril; 2008 Feb; 89(2):421-8. PubMed ID: 17572410
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Extending the treatment boundaries: Zoladex and add-back.
    Schlaff WD
    Int J Gynaecol Obstet; 1999 Feb; 64 Suppl 1():S25-31. PubMed ID: 10096462
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Current approaches to optimizing the treatment of endometriosis in adolescents.
    Laufer MR
    Gynecol Obstet Invest; 2008; 66 Suppl 1():19-27. PubMed ID: 18936548
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Gonadotrophin receptor hormone analogues in combination with add-back therapy: an update.
    McLaren JS; Morris E; Rymer J
    Menopause Int; 2012 Jun; 18(2):68-72. PubMed ID: 22611225
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Gonadotropin-releasing hormone agonist and add-back therapy: what do the data show?
    Surrey ES
    Curr Opin Obstet Gynecol; 2010 Aug; 22(4):283-8. PubMed ID: 20498596
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Evaluation of different add-back estradiol and progesterone treatments to gonadotropin-releasing hormone agonist treatment in patients with premenstrual dysphoric disorder.
    Segebladh B; Borgström A; Nyberg S; Bixo M; Sundström-Poromaa I
    Am J Obstet Gynecol; 2009 Aug; 201(2):139.e1-8. PubMed ID: 19398092
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Gonadotropin-releasing hormone analogue plus hormone replacement therapy for the treatment of endometriosis: a randomized controlled trial.
    Gregoriou O; Konidaris S; Vitoratos N; Papadias C; Papoulias I; Chryssicopoulos A
    Int J Fertil Womens Med; 1997; 42(6):406-11. PubMed ID: 9459084
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Treatment of premenstrual syndrome with gonadotropin-releasing hormone agonist in a low dose regimen.
    Sundström I; Nyberg S; Bixo M; Hammarbäck S; Bäckström T
    Acta Obstet Gynecol Scand; 1999 Nov; 78(10):891-9. PubMed ID: 10577620
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Add-back therapy in the treatment of endometriosis-associated pain.
    Zupi E; Marconi D; Sbracia M; Zullo F; De Vivo B; Exacustos C; Sorrenti G
    Fertil Steril; 2004 Nov; 82(5):1303-8. PubMed ID: 15533351
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Gonadotropin-releasing hormone agonist in the treatment of premenstrual symptoms with and without ongoing dysphoria: a controlled study.
    Freeman EW; Sondheimer SJ; Rickels K
    Psychopharmacol Bull; 1997; 33(2):303-9. PubMed ID: 9230648
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Gonadotropin-releasing hormone analogue (goserelin) plus hormone replacement therapy for the treatment of endometriosis: a randomized controlled trial.
    Howell R; Edmonds DK; Dowsett M; Crook D; Lees B; Stevenson JC
    Fertil Steril; 1995 Sep; 64(3):474-81. PubMed ID: 7641897
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.